<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482077</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;H_HCV G2 Study</org_study_id>
    <nct_id>NCT02482077</nct_id>
  </id_info>
  <brief_title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients</brief_title>
  <official_title>Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity &amp; Healthy GI and Liver Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanity &amp; Healthy GI and Liver Centre</source>
  <oversight_info>
    <authority>Hong Kong: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir
      containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes
      2 infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV RNA levels and change during and after treatment.</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on-treatment virologic breakthrough and relapse</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral breakthrough is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) during treatment, but did not achieve a sustained virologic response (SVR). Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>SOF+RBV 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF+RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+RBV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DCV 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF+DCV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DCV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOF+DCV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive LDV/SOF for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive LDV/SOF for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF+RBV</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg).</description>
    <arm_group_label>SOF+RBV 8 wk</arm_group_label>
    <arm_group_label>SOF+RBV 12 wk</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi®</other_name>
    <other_name>Copegus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF+DCV</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.</description>
    <arm_group_label>SOF+DCV 8 wk</arm_group_label>
    <arm_group_label>SOF+DCV 12 wk</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi®</other_name>
    <other_name>BMS-790052</other_name>
    <other_name>Daklinza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF 8 wk</arm_group_label>
    <arm_group_label>LDV/SOF 12 wk</arm_group_label>
    <other_name>GS-7977/GS-5885</other_name>
    <other_name>Harvoni®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age equal to or greater than 18 years, with chronic genotype 2 HCV infection;

          2. Documented HCV treatment-naïve or treatment-experienced subjects who failed previous
             PEG+RBV regimen;

          3. HCV RNA &gt; 10,000 IU/mL at Screening;

          4. Screening laboratory values within defined thresholds

          5. Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          1. Pregnant or nursing female or male with pregnant female partner;

          2. HIV or chronic hepatitis B virus (HBV) infection;

          3. Hematologic or biochemical parameters at Screening outside the protocol-specified
             requirements;

          4. Active or recent history (≤ 1 year) of drug or alcohol abuse;

          5. Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin
             cancers).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George KK Lau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanity and Health GI and Liver Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yudong Wang, PhD</last_name>
    <phone>(852)28613777</phone>
    <email>ydwang@connect.hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofeng Chen, MD</last_name>
      <phone>(8610)66933427</phone>
      <email>guofengchen302@163.com</email>
    </contact>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guofeng Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanity and Health GI and Liver Centre</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <zip>00852</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George KK Lau, MD</last_name>
      <phone>(852)28613777</phone>
      <email>gkklau@netvigator.com</email>
    </contact>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 23, 2015</lastchanged_date>
  <firstreceived_date>June 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
